Breaking News

Trials & Filings in Brief: Sept. 27, 2013

By Gil Roth | September 27, 2013

CSL Behring, Durata, Novartis, Zalicus

Filings
CSL Behring's Hizentra cleared to treat PID in Japan . . . read more

Durata files NDA for ABSSSI treatment . . . read more

Zalicus gets orphan designation for Z160 . . . read more

Post-Approval
Good data for Novartis' Lucentis . . . read more

blog comments powered by Disqus